ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements
Sarda Proteins Limited responded to a BSE query regarding recent stock price movement. The company stated the fluctuations are driven by market forces and conditions.
Sarda Proteins Limited has changed its name to Fresita Proteins Limited, effective September 21, 2026. The name change received approval from the Ministry of Corporate Affairs and BSE.
Sarda Proteins Limited filed its 35th Annual Report for the financial year ended 31st March 2026 with the stock exchange.
Sarda Proteins set its 35th AGM for September 30, 2026, with book closure September 24–30. E-voting cut-off date is September 23, 2026.
Sarda Proteins board approved convening its AGM on September 30, 2026, along with e-voting, scrutinizer, and register-closure arrangements. No financial or operational decisions were taken.
Sarda Proteins Limited has scheduled a board meeting for September 7, 2026. The agenda includes approval for the upcoming Annual General Meeting and associated administrative matters.
Sarda Proteins Limited's board approved a Rights Issue of equity shares, with an issue size not exceeding ₹100 Crore. A committee was formed to oversee the process.
Sarda Proteins Ltd reported revenue from operations of ₹0.7 Cr and net profit of ₹0.7 Cr for Q4 FY26.
Sarda Proteins Limited announced designation changes for five directors, including transitions from Additional Director to various board roles, effective July 30, 2026.
Sarda Proteins increased its authorized share capital from 13,000,000 to 100,000,000 equity shares. The change involves an authorized capital restructure approved on July 30, 2026.
Sarda Proteins Ltd has scheduled a board meeting for August 5, 2026. The board will consider a proposal for fund raising through various equity-linked securities.
Sarda Proteins Ltd held an EGM to approve authorised capital increase, company name change to Fresita Proteins Limited, and several director appointments.
Sarda Proteins announced a board and management reshuffle, including the appointment of a new Managing Director and CFO, alongside the resignation of several directors.
Sarda Proteins Limited filed a revised outcome for their July 4, 2026 board meeting. The company additionally approved a change in its corporate name.
Sarda Proteins issued an EGM addendum for July 30, 2026. Agenda items include appointing M/s A H Mandaliya & Associates as auditors and regularizing Ms. Minal Surendra Jain.
Sarda Proteins Limited appointed Ms. Minal Surendra Jain as Non-Executive Independent Director. The appointment is for a five-year term effective July 15, 2026.
Sarda Proteins Ltd reported revenue from operations of ₹13 Cr (+18.2% YoY) and net profit of ₹1.7 Cr for Q1 FY27.
Sarda Proteins scheduled a board meeting on July 15, 2026. The board will consider and approve unaudited financial results for the June quarter.
Sarda Proteins Ltd announces an EGM on 30 July 2026 to vote on capital increase, MOA amendment, and director appointments. The notice also proposes a company name change to 'Sarda Enterprises Limited'.
Sarda Proteins Ltd's board approved capital increase and key management changes. Appointments include a new Managing Director and CFO, pending shareholder approval.
Onix Renewable Ltd made an open offer for Sarda Proteins Ltd at ₹115/share. The offer size is ₹19.90 Crore for 17.30 lakh shares.
Sarda Proteins Ltd scheduled a board meeting for July 4, 2026. Agendas include increasing authorised equity share capital and altering the MOA.
Onix Renewable Limited launched a ₹19.90 Crore open offer for Sarda Proteins Limited. The bid targets 19.28% equity at ₹115 per share to acquire control.
Sarda Proteins Ltd filed a non-applicability certificate for SEBI LODR Regulations 24A and 23(9). The company remains exempt based on paid-up capital and net worth thresholds.
Sarda Proteins Ltd reported revenue from operations of ₹0.7 Cr and net profit of ₹0.8 Cr for Q4 FY26.
Sarda Proteins Ltd reported standalone audited financial results for FY26, with total revenue reaching ₹16.51 Crore and a net profit of ₹0.64 Crore. The Board approved these results on April 30, 2026, noting an unmodified audit opinion from statutory auditors.
Sarda Proteins Ltd has scheduled a Board of Directors meeting on April 30, 2026. The board will consider and approve standalone audited financial results for the quarter and year ended March 31, 2026. The trading window remains closed until 48 hours after the results declaration.
Fresita Proteins Ltd reported a net loss of ₹0.1 Cr for Q3 FY26.